Nils Arvold,MD

Board certification
Radiation Oncology, American Board of Radiology

Why Dr. Arvold went into medicine
"I wanted to help patients navigate the complex and anxiety-provoking world of cancer, and stay on top of a changing treatment landscape. I aim to teach patients about their disease and listen to their preferences as individuals to help make joint decisions on what treatment suits them best."

Professional interests
"I remain active with clinical research, and in 2019 became the Medical Director for the Whiteside Institute for Clinical Research, with an interest in expanding clinical research opportunities for collaboration between St. Luke’s physicians and the University of Minnesota Medical School, Duluth. I have served as an ad hoc reviewer for over 15 medical journals. I enjoy teaching, giving talks about cancer and helping to provide multidisciplinary cancer care at Aspirus St. Luke's Regional Cancer Center."

Hometown 
Duluth, MN

Hobbies
"I enjoy cross-country skiing, trail running, gravel & mountain biking, traveling and spending time outside with my wife and three children."

Background
Prior to joining St. Luke’s, Dr. Arvold practiced in Boston at Brigham and Women’s Hospital, Dana-Farber Cancer Institute and Children’s Hospital Boston. He was an assistant professor at Harvard Medical School and has 50 peer-reviewed publications to date. He served as Director of the radiation oncology fellowship program at Brigham and Women’s Hospital. He has won numerous awards, including the American Society of Clinical Oncology Merit award, and is a co-investigator on a K18 award from the National Institutes of Health.

Dr. Arvold was a Presidential Scholar and an NCAA Academic All-American skier while completing his undergraduate education at Dartmouth College. He was also a member of the U.S. Biathlon Team.

Awards
St. Luke’s Foundation Grant Recipient (Radiotherapy with Virtual Reality), 2018
Harvard Medical School Excellence in Teaching, 2013-2014 and 2014-2015
Brigham & Women’s Institute for the Neurosciences Seed Grant Recipient, 2013
Joint Center for Radiation Therapy Foundation Grant Recipient, 2013
ASCO Cancer Foundation Merit Award, 2011
Radiological Society of North America Research Grant Recipient, 2010-2012

Publications
Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD. Brain metastases. Nature Reviews Disease Primers 2019 Jan 17;5(1):5.
Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology 2018 Jun 18;20(7):897-906.
Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. Journal of Neuro-oncology 2017 Dec;135(3):581-591.
 Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engleman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Estimating survival in patients with lung cancer and brain metastases: an update of the Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncology 2017 Jun 1;3(6):827-831.
Arvold ND, Cefalu M, Wang Y, Zigler CM, Schrag D, Dominici F. Comparative
effectiveness of radiotherapy with vs. without temozolomide in older patients with
glioblastoma. Journal of Neuro-oncology 2017 Jan;131(2):301-311.
 Arvold ND, Heidari P, Kunawudhi A, Sequist LV, Mahmood U. Tumor hypoxia response after targeted therapy in EGFR-mutant non-small cell lung cancer: proof of concept for FMISO-PET. Technology in Cancer Research & Treatment 2016 Apr;15(2):234-242.
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning M, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended survival and prognostic factors for patients with ALK rearranged NSCLC and brain metastasis. Journal of Clinical Oncology 2016 Jan 10;34(2):123-129.
Russo AL, Arvold ND, Niemierko A, Wong N, Wong JS, Bellon JR, Punglia RS, Golshan M, Troyan SL, Brock JE, Harris JR. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Research and Treatment 2013 Jul;140(2):353-361.
Arvold ND, Punglia RS, Hughes ME, Jiang W, Edge SB, Javid SH, Laronga C, Niland JC, Theriault RL, Weeks JC, Wong YN, Lee SJ, Hassett MJ. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer 2012 Dec 15;118(24):6022-6030.
Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Barriers to the implementation of surveillance for stage I testicular seminoma. International Journal of Radiation Oncology * Biology * Physics 2012 Oct 1;84(2):383-389.
 Arvold ND, Niemierko A, Broussard GP, Adams J, Fullerton B, Loeffler JS, Shih HA. Projected second tumor risk and dose to neurocognitive structures after proton vs. photon radiotherapy for benign meningioma. International Journal of Radiation Oncology * Biology * Physics 2012 Jul 15;83(4)e495-500.
 Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Wadlow RC, Fernandez-del Castillo C, Hong TS. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012 Jun 15;118(12):3026-3035.
Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. Journal of Clinical Oncology 2011 Oct 10;29(29):3885-3891.
Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Bañez LL, Katin MJ, Braccioforte MH, D’Amico AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. Journal of Urology 2011 Jul;186(1):91-96.
Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D. Epidermal growth factor receptor, protein kinase B /Akt, and glioma response to erlotinib. Journal of the National Cancer Institute 2005 Jun 15;97(12):880-887.